Sugammadex and Neostigmine at Residual Neuromuscular Blockade
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare recovery times after reversal of a residual neuromuscular
block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.